These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 27959735)

  • 1. Perioperative Ledipasvir-Sofosbuvir for HCV in Liver-Transplant Recipients.
    Levitsky J; Verna EC; O'Leary JG; Bzowej NH; Moonka DK; Hyland RH; Arterburn S; Dvory-Sobol H; Brainard DM; McHutchison JG; Terrault NA
    N Engl J Med; 2016 Nov; 375(21):2106-2108. PubMed ID: 27959735
    [No Abstract]   [Full Text] [Related]  

  • 2. Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation.
    Kawaoka T; Imamura M; Morio K; Nakamura Y; Tsuge M; Nelson Hayes C; Kawakami Y; Aikata H; Ochi H; Ishiyama K; Ohdan H; Chayama K
    Clin J Gastroenterol; 2017 Apr; 10(2):179-184. PubMed ID: 28224470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ledipasvir and sofosbuvir for recurrent hepatitis C after liver transplantation.
    Oya Y; Sugawara Y; Watanabe T; Yoshimaru Y; Honda M; Hashimoto S; Yoshii D; Isono K; Hayashida S; Yamamoto H; Tanaka M; Sasaki Y; Inomata Y
    Biosci Trends; 2017 Jan; 10(6):496-499. PubMed ID: 27990005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.
    Abergel A; Asselah T; Metivier S; Kersey K; Jiang D; Mo H; Pang PS; Samuel D; Loustaud-Ratti V
    Lancet Infect Dis; 2016 Apr; 16(4):459-64. PubMed ID: 26803446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
    Gane EJ; Hyland RH; An D; Svarovskaia E; Pang PS; Brainard D; Stedman CA
    Gastroenterology; 2015 Nov; 149(6):1454-1461.e1. PubMed ID: 26261007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
    Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
    Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of a hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA-negative liver transplant recipient.
    Campos-Varela I; Agudelo EZ; Sarkar M; Roberts JP; Terrault NA
    Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29125670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C.
    Keating GM
    Drugs; 2015 Apr; 75(6):675-85. PubMed ID: 25837989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Curing the historically incurable: treatment success with ledipasvir/sofosbuvir for chronic hepatitis C virus in a heavily treatment-experienced individual.
    Johnson SW; Davis MM; Stever LM; Priest DH
    J Clin Pharm Ther; 2016 Dec; 41(6):727-729. PubMed ID: 27670742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of on-treatment HCV RNA during direct antiviral therapy using two different COBAS TaqMan HCV assays.
    Vermehren J; Bourlière M; Pol S; Marcellin P; Hyland RH; Jiang D; Brainard DM; Zeuzem S; Welzel TM
    J Clin Virol; 2017 Apr; 89():51-56. PubMed ID: 28259054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of donor-derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens.
    Shah AP; Cameron A; Singh P; Frank AM; Fenkel JM
    Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28060446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of the Treatment of Chronic Hepatitis C Virus Infection Genotype 2 by the Combination Sofosbuvir/Ledipasvir in a Black African Kidney Transplant.
    Lawson-Ananissoh LM; Anzouan-Kacou YHK; Tsevi YM; Ackoundou-N'Guessan KC; Attia KA
    West Afr J Med; 2019; 36(3):280-282. PubMed ID: 31622492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting.
    Beinhardt S; Al Zoairy R; Ferenci P; Kozbial K; Freissmuth C; Stern R; Stättermayer AF; Stauber R; Strasser M; Zoller H; Watschinger B; Schmidt A; Trauner M; Hofer H; Maieron A
    Transpl Int; 2016 Sep; 29(9):999-1007. PubMed ID: 27203857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Ledipasvir in Renal Transplant Recipients.
    Eisenberger U; Guberina H; Willuweit K; Bienholz A; Kribben A; Gerken G; Witzke O; Herzer K
    Transplantation; 2017 May; 101(5):980-986. PubMed ID: 27495770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Membranous nephropathy associated with hepatitis C virus infection treated with corticosteroids and Ledipasvir-Sofosbuvir: a case report and review of literature.
    Weng Q; Li X; Ren H; Xie J; Pan X; Xu J; Chen N
    Oncotarget; 2017 Mar; 8(13):22299-22303. PubMed ID: 28223549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ledipasvir-sofosbuvir for hepatitis C genotype 4 infection.
    Smith MA; Mohammad RA
    Lancet Infect Dis; 2015 Sep; 15(9):993-995. PubMed ID: 26187029
    [No Abstract]   [Full Text] [Related]  

  • 17. [Debut in diabetic patients with hepatitis C treatment with ledipasvir/ sofosbuvir (Harvoni®)].
    Vicente-Sánchez S; Menéndez Naranjo L
    Farm Hosp; 2017 Mar; 41(2):313-314. PubMed ID: 28236804
    [No Abstract]   [Full Text] [Related]  

  • 18. Hepatitis B reactivation in a chronic hepatitis C patient treated with ledipasvir and sofosbuvir: A case report.
    Ou P; Fang Z; Chen J
    Clin Res Hepatol Gastroenterol; 2017 Mar; 41(2):e17-e18. PubMed ID: 27601170
    [No Abstract]   [Full Text] [Related]  

  • 19. Direct antiviral agents for treatment-naïve patients with genotype 1 hepatitis C: A statistical model for comparing outcomes between real world and clinical trials.
    Messori A; Brunetto MR; De Luca A; Zignego AL
    Dig Liver Dis; 2015 Nov; 47(11):988-9. PubMed ID: 26205830
    [No Abstract]   [Full Text] [Related]  

  • 20. Successful treatment of sexually acquired acute HCV reinfection with ledipasvir/sofosbuvir in a HIV-infected patient.
    Sollima S; Antinori S; Torre A; Binda F; Giacomelli A; Milazzo L
    Int J STD AIDS; 2017 Jul; 28(8):838-840. PubMed ID: 28632109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.